S
Stryker Corporation
SYK · Healthcare
Q4 FY2025
Earning ended Dec 31, 2025Report generated Mar 10, 2026
Mako Is an Implant Subscription Hiding Inside a Robot
The market prices Stryker as a premium medical device manufacturer; the more accurate frame is that it's a surgical operating system with a recurring consumables model, and the installed base is still in the early-to-middle innings of global hospital penetration. Every Mako unit placed today is not a hardware sale — it's a decade-long commitment from a surgeon and a hospital to Stryker's implant ecosystem, and that distinction changes the quality of growth being purchased at the current multiple.
Flowly Score
Apr 16 Close
+15%$338.38
Fair Value
$390.00
65
Strongat $338.38
Business Strength8/10
Mako is not a product category — it's a decade-long implant annuity disguised as capital equipment, and the installed base flywheel is still in early innings globally. The commercial culture, switching cost stack across MedSurg and Orthopaedics, and early surgical robotics conviction create a moat that is actively widening, not merely maintaining.
Financial Resilience7/10
Cash generation is unambiguously real — OCF clears net income every year, CapEx runs light, and FCF conversion is accelerating to multi-year highs. The debt load from serial acquisitions is the one structural drag, though the asset-light underlying model services it comfortably.
Growth & Trajectory8/10
Four consecutive years of double-digit organic growth at this revenue base is a rare achievement, and the mechanism — aging demographics plus Mako-driven implant pull-through — is durable rather than cyclical. The trajectory is improving, not decelerating: record Mako installations, margin expansion, and accelerating FCF conversion all point in the same direction.
Valuation5/10at $365.92
The neutral DCF scenario essentially kisses the current price, meaning buyers today are paying full freight for a flawless execution path with almost no margin of safety. Current multiples sit below their five-year averages, which provides modest comfort, but the FCF yield and earnings yield together signal a business priced to compound rather than priced to outperform.
Risk6/10
The most concrete risk is not a competitor — it's CMS reimbursement policy, which could reprice the entire robotic surgery thesis overnight if coverage determinations shift away from premium procedure rates. Secondary risks are real but slower-moving: ASC migration pressuring the capital-equipment bundle model, and a single large M&A misstep that deploys the war chest into a category that doesn't materialize.
Stryker sits at the intersection of a genuinely durable moat and a price that already knows it. The business quality is not in question: wide gross margins earned through structural indispensability, OCF that consistently outpaces reported earnings, four consecutive years of double-digit organic growth at scale, and a Mako flywheel that converts every new robot placement into years of locked-in implant revenue. The question is whether the current valuation leaves room for the investor to win alongside the business, and the honest answer is: barely, on the base case. Where this business is heading is more interesting than where it is. Mako knee penetration is still materially below hip penetration, and knees represent the higher-volume procedure — closing that gap alone is a multi-year growth driver before layering in shoulder, spine, and revision applications just now launching on Mako 4. The ambulatory surgery center shift is the counterweight: as joint replacement migrates out of hospital ORs, the economics of placing a large capital robot change, and Stryker's handheld RPS is a direct acknowledgment that the premium bundled model needs a flanking product for that channel. Execution on that transition will define whether the growth trajectory holds through the decade or moderates. The single most specific risk is a CMS reimbursement decision that removes or caps the premium attached to robotic-assisted procedures. Switching costs are high but conditional — they rest on the assumption that robotic surgery commands clinical and reimbursement superiority. If outcomes-based payment models force transparent head-to-head comparisons and Mako can't demonstrate statistically superior long-term patient outcomes over conventional technique, the reimbursement case weakens, robot placement economics deteriorate, and the entire installed-base flywheel slows simultaneously. That is a low-probability but high-magnitude scenario that the current valuation does not meaningfully discount.